Id Counterfeit Pharmaceuticals with Portable Raman
Rigaku
After eight months of negotiations Roche and Genentech have reached an agreement, with the Swiss pharma buying out the US biotech for $46.8bn (€36.6bn).
The deal now looks set to go through at $95 a share, falling well short of the $112 that Genentech has alleged to have valued itself at. However, the financial markets have taken a significant downturn since then and Genentech believes the price is “fair”.
Perhaps crucially for Roche the deal comes before the release of Avastin trial data, which if positive could send Genentech’s share price past the $100 mark.
